Figure 4.

NR2F1‐AS1 sponged miR‐363 with complementary binding at 3′‐UTR. A, Schematic diagram demonstrated the complementary bound within miR‐363 and NR2F1‐AS1 3′‐UTR with binding sites predicted by bioinformatics programs (StarBase V 2.0, http://starbase.sysu.edu.cn/mirLncRNA). B, Luciferase reporter gene assay was performed in HEK‐293T cells transfected with NR2F1‐AS1 wild/mutant type and miR‐363 mimics/control. C, miR‐363 expression levels were measured in oxaliplatin‐resistant cell lines and parental cell lines using RT‐PCR. D, RT‐PCR showed the miR‐363 expression levels in Huh7/OXA and HepG2/OXA cells transfected with NR2F1‐AS1 siRNA or empty vector. E, miR‐363 was measured in 15 pairs of oxaliplatin‐resistant hepatocellular carcinoma (HCC) samples and oxaliplatin‐sensitive samples. Data were expressed as mean ± SD. *P < .05 represents the statistical difference